Tag: Ryanodine receptor

Malignant hyperthermia (MH) is a life-threatening, inherited pharmacogenetic disorder with a mortality rate that has drastically decreased due to effective treatment. A key part of this treatment involves Ryanodex (dantrolene sodium), and understanding **how does Ryanodex work** is crucial for its rapid deployment in a crisis situation.

Since the introduction of dantrolene in the 1980s, the mortality rate of malignant hyperthermia (MH) has dramatically decreased from 70–80% to less than 10%. This significant improvement highlights the life-saving role of this unique muscle relaxant, but what does dantrolene do beyond treating this rare emergency?